BAI Yun, XIE Ming-ying, HUANG Bo-ling, et al. Preventive and Therapeutic Effect of Yangsheng Yishen Decoction on Early Staged Diabetic Nephropathy (DN) with Deficiency of Both Qi and Yin[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(2): 169-174.
DOI:
BAI Yun, XIE Ming-ying, HUANG Bo-ling, et al. Preventive and Therapeutic Effect of Yangsheng Yishen Decoction on Early Staged Diabetic Nephropathy (DN) with Deficiency of Both Qi and Yin[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(2): 169-174. DOI: 10.13422/j.cnki.syfjx.2017020169.
Preventive and Therapeutic Effect of Yangsheng Yishen Decoction on Early Staged Diabetic Nephropathy (DN) with Deficiency of Both Qi and Yin
Objective: To discuss the clinical efficacy of Yangsheng Yishen decoction on delaying the disease for early staged diabetic nephropathy (DN) with deficiency of both Qi and Yin and observe its effects on levels of tumor necrosis factor-α (TNF-α)
transforming growth factor-β (TGF-β)
platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). Method: One hundred and seventy patients were randomly divided into western medicine group (85 cases) and integrated Chinese and western medicine group (85 cases) by random number table. Patients in western medicine group received lifestyle guidance; controlled their blood glucose and blood pressure
corrected lipid metabolism disorders; took Irbesartan tablets
1 tablet/day. Based on the treatment in western medicine group
patients in integrated Chinese and western medicine group added Yangsheng Yishen decoction
1 dose/day. The treatment course was 6 months for both groups
and the patients were followed up for 18 months. Outcome events during 24 months were recorded
such as development of DN stage Ⅲ into DN stage Ⅳ
and increase of creatinine (SCr) by 1 fold. Levels of urinary albumin excretion rate (UAER)
serum creatinine (SCr)
fasting blood-glucose (FBG)
glycosylated hemoglobin (HbAlc)
serum creatinine (SCr)
fasting blood glucose (FBG)
glycosylated hemoglobin (HbAlc)
blood lipids Include cholesterol (TC)
triglyceride (TG)
high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) and urinary albumin/creatinine ratio (ACR) were detected. Scores of deficiency of both Qi and Yin were graded; the levels of TNF-α
TGF-β
PDGF and VEGF were detected. Result: Ridit analysis showed that the clinical efficacy in integrated Chinese and western medicine group was superior to that in western medicine group (P<0.05). Occurrence rate of outcome events in integrated Chinese and western medicine group was 7.41%
lower than 19.51% in western medicine group (χ2=5.113
P<0.05). At the 3th month after treatment
ACR in integrated Chinese and western medicine group was decreased and was lower than that in control group at the same period (P<0.05). At the 6th month after treatment
levels of UAER
SCr
ACR
HbAlc and LDL-C in integrated Chinese and western medicine group were all lower than those in western medicine group (P<0.05)
but the level of HDL-C was higher than that in western medicine group (P<0.05). Scores of deficiency of both Qi and Yin in integrated Chinese and western medicine group were lower than those in western medicine group at the 3th and 6th month after treatment (P<0.05). Levels of TNF-α
TGF-β
PDGF and VEGF were lower than those in western medicine group after treatment. Conclusion: Yangsheng Yishen decoction combined with conventional western medicine treatment can protect renal function and delay state of an illness
and reduce the incidence of outcome events in early staged DN
and its mechanism of action may be associated with reducing levels of TNF-α
Effect of Xuanfei Pingchuan Capsules on Rat COPD Model
Effect of Bushen Formulae on T Helper Cell 1, 17 and Regulatory T cell in Experimental Autoimmune Encephalomyelitis Mice
Effect of Astragalus Injection on Urinary Albumin and Cytokines in Patients with Early Diabetic Nephropathy
Clinical Efficacy and Mechanism of Xiaozheng Yin in Treatment of Endometriosis
Efficacy of Qingre Jiedu Huoxue Tongluo Formula Combined with Fufang Huangbai Liquid for Diabetic Foot
Related Author
XUE Xiao-ming
WANG Yang
ZHAO Qin-ping
GUAN Wei
ZHANG Li
CHEN Xu
LIU Yan
ZHANG Ping
Related Institution
Quality Control Office,Armed Police Corps Hospital of Henan
Fraditional Chinese Medicine Hospital of Zhongmu County,Zhongmu
Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan University of Chinese Medicine
Hunan University of Chinese Medicine
MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials